Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease
Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease
Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ) 42/Aβ40 and the concentration of tau
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients
A Pichet Binette, S Palmqvist, D Bali, G Farrar… - Alzheimer's Research & …, 2022 - Springer
Background Up to now, there are no clinically available minimally invasive biomarkers to
accurately identify mild cognitive impairment (MCI) patients who are at greater risk to …
accurately identify mild cognitive impairment (MCI) patients who are at greater risk to …
Relationships of cognitive measures with cerebrospinal fluid but not imaging biomarkers of Alzheimer disease vary between Black and white individuals
Objective Biomarkers of Alzheimer disease vary between groups of self‐identified Black and
White individuals in some studies. This study examined whether the relationships between …
White individuals in some studies. This study examined whether the relationships between …
Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease
There is evidence of longitudinal atrophy in posterior brain areas in early-onset Alzheimer's
disease (EOAD; aged< 65 years), but no studies have been conducted in an EOAD cohort …
disease (EOAD; aged< 65 years), but no studies have been conducted in an EOAD cohort …
Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data
Tau PET has allowed for critical insights into in vivo patterns of tau accumulation and
change in individuals early in the Alzheimer's disease (AD) continuum. A key …
change in individuals early in the Alzheimer's disease (AD) continuum. A key …
Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression
Heterogeneity in progression to Alzheimer's disease (AD) poses challenges for both clinical
prognosis and clinical trial implementation. Multiple AD-related subtypes have previously …
prognosis and clinical trial implementation. Multiple AD-related subtypes have previously …
Neurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates
Neurofilaments light chain (NfLs) are currently recognized as a marker of axonal injury and
degeneration. Their measurement in biological fluids has a promising role in the diagnosis …
degeneration. Their measurement in biological fluids has a promising role in the diagnosis …
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
Introduction Continuous measures of amyloid burden as measured by positron emission
tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study …
tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study …
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles
Alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau
tangles potentially preceding clinical symptoms by many years. Previously only detectable …
tangles potentially preceding clinical symptoms by many years. Previously only detectable …